Pre-eclampsia: pathogenesis, novel diagnostics and therapies
- PMID: 30792480
- PMCID: PMC6472952
- DOI: 10.1038/s41581-019-0119-6
Pre-eclampsia: pathogenesis, novel diagnostics and therapies
Erratum in
-
Author Correction: Pre-eclampsia: pathogenesis, novel diagnostics and therapies.Nat Rev Nephrol. 2019 Jun;15(6):386. doi: 10.1038/s41581-019-0156-1. Nat Rev Nephrol. 2019. PMID: 31068691
Abstract
Pre-eclampsia is a complication of pregnancy that is associated with substantial maternal and fetal morbidity and mortality. The disease presents with new-onset hypertension and often proteinuria in the mother, which can progress to multi-organ dysfunction, including hepatic, renal and cerebral disease, if the fetus and placenta are not delivered. Maternal endothelial dysfunction due to circulating factors of fetal origin from the placenta is a hallmark of pre-eclampsia. Risk factors for the disease include maternal comorbidities, such as chronic kidney disease, hypertension and obesity; a family history of pre-eclampsia, nulliparity or multiple pregnancies; and previous pre-eclampsia or intrauterine fetal growth restriction. In the past decade, the discovery and characterization of novel antiangiogenic pathways have been particularly impactful both in increasing understanding of the disease pathophysiology and in directing predictive and therapeutic efforts. In this Review, we discuss the pathogenic role of antiangiogenic proteins released by the placenta in the development of pre-eclampsia and review novel therapeutic strategies directed at restoring the angiogenic imbalance observed during pre-eclampsia. We also highlight other notable advances in the field, including the identification of long-term maternal and fetal risks conferred by pre-eclampsia.
Figures
Similar articles
-
Preeclampsia: Maternal Systemic Vascular Disorder Caused by Generalized Endothelial Dysfunction Due to Placental Antiangiogenic Factors.Int J Mol Sci. 2019 Aug 30;20(17):4246. doi: 10.3390/ijms20174246. Int J Mol Sci. 2019. PMID: 31480243 Free PMC article. Review.
-
Clinical implications of placenta-derived angiogenic/anti-angiogenic biomarkers in pre-eclampsia.Biomark Med. 2021 May;15(7):523-536. doi: 10.2217/bmm-2020-0545. Epub 2021 Apr 15. Biomark Med. 2021. PMID: 33856265
-
Molecular Mechanisms of Preeclampsia.Cold Spring Harb Perspect Med. 2015 Aug 20;5(10):a023473. doi: 10.1101/cshperspect.a023473. Cold Spring Harb Perspect Med. 2015. PMID: 26292986 Free PMC article. Review.
-
Placental and Renal Pathways Underlying Pre-Eclampsia.Int J Mol Sci. 2024 Feb 27;25(5):2741. doi: 10.3390/ijms25052741. Int J Mol Sci. 2024. PMID: 38473987 Free PMC article. Review.
-
New developments in the pathogenesis of preeclampsia.Adv Chronic Kidney Dis. 2013 May;20(3):265-70. doi: 10.1053/j.ackd.2013.02.003. Adv Chronic Kidney Dis. 2013. PMID: 23928392 Free PMC article. Review.
Cited by
-
Upregulation of Siglec-6 induces mitochondrial dysfunction by promoting GPR20 expression in early-onset preeclampsia.J Transl Med. 2024 Jul 22;22(1):674. doi: 10.1186/s12967-024-05505-z. J Transl Med. 2024. PMID: 39039496 Free PMC article.
-
Placenta-targeted Treatment Strategies for Preeclampsia and Fetal Growth Restriction: An Opportunity and Major Challenge.Stem Cell Rev Rep. 2024 May 30. doi: 10.1007/s12015-024-10739-x. Online ahead of print. Stem Cell Rev Rep. 2024. PMID: 38814409 Review.
-
Oxidative Stress, Lipid Peroxidation and Ferroptosis Are Major Pathophysiological Signatures in the Placental Tissue of Women with Late-Onset Preeclampsia.Antioxidants (Basel). 2024 May 11;13(5):591. doi: 10.3390/antiox13050591. Antioxidants (Basel). 2024. PMID: 38790696 Free PMC article.
-
Overexpression of RBM15 modulated the effect of trophoblast cells by promoting the binding ability between YTHDF2 and the CD82 3'UTR to decrease the expression of CD82.Heliyon. 2024 May 3;10(9):e30702. doi: 10.1016/j.heliyon.2024.e30702. eCollection 2024 May 15. Heliyon. 2024. PMID: 38765115 Free PMC article.
-
Exploiting sweet relief for preeclampsia by targeting autophagy-lysosomal machinery and proteinopathy.Exp Mol Med. 2024 May;56(5):1206-1220. doi: 10.1038/s12276-024-01234-x. Epub 2024 May 17. Exp Mol Med. 2024. PMID: 38760513 Free PMC article.
References
-
- Wallis AB, Saftlas AF, Hsia J & Atrash HK Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. Am. J. Hypertens 21, 521–526 (2008). - PubMed
-
- Duley L The global impact of pre-eclampsia and eclampsia. Semin. Perinatal 33, 130–137 (2009). - PubMed
-
- Abalos E, Cuesta C, Grosso AL, Chou D & Say L Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol 170, 1–7 (2013). - PubMed
-
- Kuklina EV, Ayala C & Callaghan WM Hypertensive disorders and severe obstetric morbidity in the United States. Obstet. Gynecol 113, 1299–1306 (2009). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous